Skip to content
lifestyle.recentlegalnews.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Fractyl Health, Inc.
Fractyl Health’s Revita Meets Six-Month Co-Primary Endpoint in Ongoing REMAIN-1 Pivotal Study, With Highly Statistically Significant Reduction in Weight Regain After GLP-1 Discontinuation
October 18, 2026
Fractyl Health to Participate in Upcoming September Investor Conferences
September 9, 2026
Fractyl Health to Host Virtual Commercial Strategy Day on Tuesday, September 1, 2026: The Potential Path to Commercializing Revita®, a Procedural Therapy for Post-GLP-1 Weight Maintenance
August 20, 2026
Fractyl Health Reports Second Quarter 2026 Financial Results and Business Updates
August 10, 2026
Fractyl Health to Report Second Quarter 2026 Financial Results and Provide Business Updates on August 10, 2026
August 3, 2026
Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates
May 12, 2026
Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes
May 11, 2026
Fractyl Health to Report First Quarter 2026 Financial Results and Provide Business Updates on May 12, 2026, and Will Participate in an Upcoming Investor Conference
May 5, 2026